EDSA - Why Is Infectious Disease Player Edesa Biotech Stock Soaring Today? | Benzinga
Edesa Biotech Inc (NASDAQ: EDSA) has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company's first-in-class therapeutic candidate.
Edesa's experimental drug, EB05 (paridiprubart), belongs to a class of therapies called Host-Directed Therapeutics (HDTs) designed to modulate the body's immune response when confronted with infectious diseases or even chemical ...